Position in LYRA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$51,103
-$488,383 QoQ
Shares Held
104,059
-40.6% QoQ
Ownership
5.86%
of shares outstanding
% of Portfolio
1.01%
of 13F equity value
Holder Rank
#1
of 1 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in LYRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026SABBY MANAGEMENT, LLC holds $972,254 across 8 Biotechnology names. LYRA ranks #6 (5.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BCTX |
BriaCell Therapeutics Corp.
|
73,915 | $309,703 | |
| 2 | MBRX |
Moleculin Biotech, Inc.
|
75,021 | $171,798 | |
| 3 | BDRX |
Biodexa Pharmaceuticals Plc
|
257,472 | $159,117 | |
| 4 | CANF |
Can-Fite BioPharma Ltd.
|
42,559 | $131,932 | |
| 5 | REVB |
Revelation Biosciences, Inc.
|
99,432 | $119,318 | |
| 6 | LYRA |
Lyra Therapeutics, Inc.
This page
|
104,059 | $51,103 | |
| 7 | TPST |
Tempest Therapeutics, Inc.
|
17,856 | $29,283 | |
| 8 | CLDI |
Calidi Biotherapeutics, Inc.
|
434,903 | $0 |
All Filings in LYRA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $51,103 | 104,059 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $539,486 | 175,158 | Shares | Defined | 2026-02-17 | |
| 2025-12-31 | $539,486 | 175,158 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $832,874 | 127,624 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,126,531 | 125,729 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||